COMMUNIQUÉS West-GlobeNewswire

LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia
31/07/2025
VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States First once daily solution to [...]
CapsoVision to Release Second Quarter 2025 Financial Results on Thursday, August 14, 2025
31/07/2025
- Conference Call Scheduled for Thursday, August 14, 2025 at 4:30 pm ET - SARATOGA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops [...]
Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman Syndrome
31/07/2025
Company expects to complete Phase 3 Aspire study in the second half of 2026 Aurora study of GTX-102 in additional ages and genotypes on track to initiate in the second half of 2025 NOVATO, Calif., July 31, 2025 (GLOBE [...]
Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025
31/07/2025
Year-over-year revenue grows 10% , operating profit up 19% , non-GAAP operating profit up 19% Operating cash flow of $539 million Quarterly dividend increases 13% to $0.60 per share Note: A webcast of Resmed’s [...]
OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results
31/07/2025
Conference call begins at 4:30 p.m. Eastern time today MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June [...]
Safety Shot Appoints Markita Russell as Chief Financial Officer
31/07/2025
SCOTTSDALE, AZ, July 31, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or the “Company”) today announced the appointment of Markita L. Russell as its new Chief Financial Officer. Ms. Russell, [...]
4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update
31/07/2025
4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level 4D-150 demonstrated durable and dose-dependent clinical activity with sustained gains in visual acuity and [...]
Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025
31/07/2025
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational [...]
Lifecore Biomedical to Report Fourth Quarter and Fiscal Year 2025 Financial Results on August 7, 2025
31/07/2025
Webcast Scheduled for Thursday, August 7 at 4:30 p.m. Eastern CHASKA, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated contract development and [...]
Seer to Participate in the Canaccord Genuity 45th Annual Growth Conference
31/07/2025
REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the [...]
iSpecimen Inc. Announces Pricing of Approximately $1.75 Million Private Placement Priced At-the-Market
31/07/2025
WOBURN, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a [...]
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
31/07/2025
BALA CYNWYD, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today [...]
Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform
31/07/2025
Strengthening technology innovation and leadership of the Certara AI/ML-enabled biosimulation platform used to speed time to market in drug discovery and development RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- [...]
Rapid Micro Biosystems to Announce Second Quarter 2025 Financial Results on August 12, 2025
31/07/2025
LEXINGTON, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to [...]
FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
31/07/2025
HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of [...]
Precipio Announces Q2-2025 Shareholder Update Call
31/07/2025
Conference Call to be held on August 14th, 2025 at 5:00 PM EST NEW HAVEN, Conn., July 31, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q2-2025 [...]
Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
31/07/2025
REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc . (Coherus, Coherus Oncology or the Company, Nasdaq: CHRS), today announced that its second quarter 2025 financial results will be released [...]
Pacific Health Care Organization, Inc. Reports its Second Quarter 2025 Financial Results
31/07/2025
Irvine, July 31, 2025 (GLOBE NEWSWIRE) -- Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) today filed with the Securities and Exchange Commission (the “SEC”) its quarterly report on Form 10-Q [...]
Press release: Use of alfapump® to control ascites enabling elective umbilical hernia repair published in Hernia
31/07/2025
Use of alfapump® to control ascites enabling elective umbilical hernia repair published in Hernia Untreated umbilical hernias occur in 20% of patients with ascites due to liver cirrhosis. Without treatment, there is a [...]

Pages